Clinical lung cancer最新文献

{"title":"Physical exercise during neoadjuvant treatments for non-small cell lung cancer: the time is coming","authors":"Alice Avancini, Diana Giannarielli, Lorenzo Belluomini, Federico Schena, Michele Milella, Sara Pilotto","doi":"10.1016/j.cllc.2024.07.015","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.015","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients","authors":"Prerana Jha, Asim Joshi, Rohit Mishra, Ranendra Pratap Biswal, Pooja Mahesh Kulkarni, Sewanti Limaye, Govind Babu, Ullas Batra, Prabhat Malik, Rajiv Kumar, Minit Shah, Nandini Menon, Amit Rauthan, Moni Kuriakose, Venkataramanan Ramachandran, Vanita Noronha, Prashant Kumar, Kumar Prabhash","doi":"10.1016/j.cllc.2024.07.011","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.07.011","url":null,"abstract":"The genomic landscape of non-small cell lung cancer (NSCLC) in the Indian patients remains underexplored. We revealed distinctive genomic alterations of Indian NSCLC patients, thereby providing vital molecular insights for implementation of precision therapies. We analyzed the genomic profiles of 325 lung adenocarcinoma and 81 lung squamous carcinoma samples from Indian patients using targeted sequencing of 50 cancer related genes. Correlations between genomic alterations and clinical characteristics were computed using statistical analyses. Additionally, we identified distinct features of Indian NSCLC genomes by comparison across different ethnicities. Our genomic analysis revealed several noticeable features of Indian NSCLC patients. Alterations in (45.8%), (27.4%), (11.4%) and (10.2%) were predominant in adenocarcinoma, with 68% eligible for targeted therapies. Squamous carcinoma exhibited prevalent alterations in (40.7%), (17.3%), and (8.6%). We observed higher frequency of alterations (18.5%) in lung squamous carcinoma patients, significantly distinct from other ethnicities reported till date. Beyond established correlations, we observed 60% of PD-L1 negative squamous patients harbored TP53 alterations, suggesting intriguing therapeutic implications. Our data revealed unique genomic variations of adenocarcinoma and squamous carcinoma patients, with significant indications for precision medicine and clinical practice of lung cancers. The study emphasizes the importance of clinical utility of NGS for routine diagnostics.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk","authors":"Olivia H. Chen, Wesley K.Y. Wong, Kevin K.S. Mok, Landon L. Chan, Candy Tang, Molly S.C. Li","doi":"10.1016/j.cllc.2024.06.012","DOIUrl":"https://doi.org/10.1016/j.cllc.2024.06.012","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer","authors":"","doi":"10.1016/j.cllc.2024.06.011","DOIUrl":"10.1016/j.cllc.2024.06.011","url":null,"abstract":"<div><h3>Purpose</h3><p>Immune Checkpoint Inhibitor (ICI) regimens are approved for first-line treatment of metastatic nononcogene-driven NSCLC. Guidelines do not differentiate which patients with PD-L1 ≥ 50% should receive ICI monotherapy. The clinically validated PROphet NSCLC plasma proteomic-based test is designed to inform this therapeutic decision.</p></div><div><h3>Methods</h3><p>One hundred oncologists were presented with 3 “virtual” metastatic NSCLC cases with PD-L1 scores and asked to recommend an approved first-line regimen. They then watched an online educational webinar on the PROphetNSCLC test. Postwebinar, the same cases were represented with the addition of a PROphet result, and oncologists again recommended a first-line regimen. Responses were compared to assess the impact on first-line treatment selection.</p></div><div><h3>Results</h3><p>Treatment recommendation changed in 39.6% of PROphet-tested cases, with 93% of physicians changing at least 1 case. In the PD-L1 ≥ 50% group, 89% of physicians changed their recommendation, followed by 77%, in PD-L1 &lt; 1%, and 36% in PD-L1 1% to 49%. ​In the PD-L1 ≥ 50%, PROphet POSITIVE group, the recommendation for ICI monotherapy increased from 60% to 89%. ​For the PD-L1 ≥ 50%, PROphet NEGATIVE group, the recommendation for monotherapy dropped from 60% to 9%. In the PD-L1 &lt; 1%, PROphet NEGATIVE group, 35% of patients were spared toxicity from ICI compared to 11% in PROphet untested cases.</p></div><div><h3>Conclusion</h3><p>Adding PROphet to PD-L1 expression impacted therapeutic decision making in first-line NSCLC. PROphet identifies those predicted to have an overall survival benefit from ICI monotherapy versus combination versus chemotherapy, improving the probability of efficacy and reducing toxicity for some patients.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424001384/pdfft?md5=68fe4e60e1c9153f5469964a5f1d6d04&pid=1-s2.0-S1525730424001384-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer","authors":"","doi":"10.1016/j.cllc.2024.06.010","DOIUrl":"10.1016/j.cllc.2024.06.010","url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>The incidence of brain radiation necrosis is increasing in NSCLC patients undergoing radiotherapy for brain metastases.</p></span></li><li><span>•</span><span><p>[¹¹C] methionine–PET and MRS are valuable tools for diagnosing brain radiation necrosis.</p></span></li><li><span>•</span><span><p>Bevacizumab is an effective treatment for brain radiation necrosis in patients with nonsquamous NSCLC.</p></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424001359/pdfft?md5=6792b8d4e751aaccaf770a85083f2252&pid=1-s2.0-S1525730424001359-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-driven Characterization of Solid Pulmonary Nodules on CT Imaging for Enhanced Malignancy Prediction in Small-sized Lung Adenocarcinoma","authors":"Yujin Kudo ,&nbsp;Taiyo Nakamura ,&nbsp;Jun Matsubayashi ,&nbsp;Akimichi Ichinose ,&nbsp;Yushi Goto ,&nbsp;Ryosuke Amemiya ,&nbsp;Jinho Park ,&nbsp;Yoshihisa Shimada ,&nbsp;Masatoshi Kakihana ,&nbsp;Toshitaka Nagao ,&nbsp;Tatsuo Ohira ,&nbsp;Jun Masumoto ,&nbsp;Norihiko Ikeda","doi":"10.1016/j.cllc.2024.04.015","DOIUrl":"10.1016/j.cllc.2024.04.015","url":null,"abstract":"<div><h3>Objectives</h3><p>Distinguishing solid nodules from nodules with ground-glass lesions in lung cancer is a critical diagnostic challenge, especially for tumors ≤2 cm. Human assessment of these nodules is associated with high inter-observer variability, which is why an objective and reliable diagnostic tool is necessary. This study focuses on artificial intelligence (AI) to automatically analyze such tumors and to develop prospective AI systems that can independently differentiate highly malignant nodules.</p></div><div><h3>Materials and methods</h3><p>Our retrospective study analyzed 246 patients who were diagnosed with negative clinical lymph node metastases (cN0) using positron emission tomography-computed tomography (PET/CT) imaging and underwent surgical resection for lung adenocarcinoma. AI detected tumor sizes ≤2 cm in these patients. By utilizing AI to classify these nodules as solid (AI_solid) or non-solid (non-AI_solid) based on confidence scores, we aim to correlate AI determinations with pathological findings, thereby advancing the precision of preoperative assessments.</p></div><div><h3>Results</h3><p>Solid nodules identified by AI with a confidence score ≥0.87 showed significantly higher solid component volumes and proportions in patients with AI_solid than in those with non-AI_solid, with no differences in overall diameter or total volume of the tumors. Among patients with AI_solid, 16% demonstrated lymph node metastasis, and a significant 94% harbored invasive adenocarcinoma. Additionally, 44% were upstaging postoperatively. These AI_solid nodules represented high-grade malignancies.</p></div><div><h3>Conclusion</h3><p>In small-sized lung cancer diagnosed as cN0, AI automatically identifies tumors as solid nodules ≤2 cm and evaluates their malignancy preoperatively. The AI classification can inform lymph node assessment necessity in sublobar resections, reflecting metastatic potential.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140928510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review","authors":"Parth Sharma ,&nbsp;Himil Mahadevia ,&nbsp;Sreekanth Donepudi ,&nbsp;Lara Kujtan ,&nbsp;Beth Gustafson ,&nbsp;Ben Ponvilawan ,&nbsp;Ammar Al-Obaidi ,&nbsp;Janakiraman Subramanian ,&nbsp;Dhruv Bansal","doi":"10.1016/j.cllc.2024.04.009","DOIUrl":"10.1016/j.cllc.2024.04.009","url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>While most molecular testing focuses on somatic alterations in patients with non-small cell lung cancer, evidence is growing regarding the presence of germline lung cancer mutations. The most common lung cancer germline mutation is EGFR T790M.</p></span></li><li><span>•</span><span><p>Herein, we describe an EGFR germline mutation not previously reported outside of Asia, T725M.</p></span></li><li><span>•</span><span><p>Identification of germline lung cancer mutations could help to identify new therapeutic targets. Furthermore, further characterization of these mutations can aid in the development of screening and surveillance guidelines for patients with hereditary lung cancer, which currently do not exist.</p></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000524/pdfft?md5=9135c62f62eeb19fdc77fa14f8ab402b&pid=1-s2.0-S1525730424000524-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis","authors":"Amit A. Kulkarni ,&nbsp;Cassandra Hennessy ,&nbsp;Grace Wilson ,&nbsp;Vidhyalakshmi Ramesh ,&nbsp;Clara Hwang ,&nbsp;Joy Awosika ,&nbsp;Ziad Bakouny ,&nbsp;Hina Khan ,&nbsp;Diana Vilar-Compte ,&nbsp;Rana McKay ,&nbsp;Chinmay Jani ,&nbsp;Lisa Weissmann ,&nbsp;Elizabeth Griffiths ,&nbsp;Gerald Batist ,&nbsp;Nathaniel Bouganim ,&nbsp;Blanche Mavromatis ,&nbsp;Babar Bashir ,&nbsp;Ryan H. Nguyen ,&nbsp;Jonathan W. Riess ,&nbsp;Matthew Puc ,&nbsp;Narjust Florez","doi":"10.1016/j.cllc.2024.04.003","DOIUrl":"10.1016/j.cllc.2024.04.003","url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>Patients with thoracic cancers and COVID-19 have high mortality and morbidity.</p></span></li><li><span>•</span><span><p>Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.</p></span></li><li><span>•</span><span><p>We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).</p></span></li><li><span>•</span><span><p>As opposed to immunotherapy or targeted therapy, recent (&lt;3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.</p></span></li><li><span>•</span><span><p>None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.</p></span></li><li><span>•</span><span><p>Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.</p></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A patient with a Germline (p.R776H) EGFR Mutation With Multiple Lung Cancers Harboring Different Somatic EGFR Mutations","authors":"Iacopo Petrini ,&nbsp;Rossella Bruno ,&nbsp;Iosè Di Stefano ,&nbsp;Vittorio Aprile ,&nbsp;Stylianos Korasidis ,&nbsp;Eleonora Pardini ,&nbsp;Antonio Chella ,&nbsp;Greta Alì","doi":"10.1016/j.cllc.2024.04.007","DOIUrl":"10.1016/j.cllc.2024.04.007","url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>There are not standard guidelines for the selection and treatment of patients with synchronous multiple nodules with ground glass/lepidic features.</p></span></li><li><span>•</span><span><p>The presence of different <em>EGFR</em> mutations in the various resected nodules with ground glass/lepidic features suggests the existence of multifocal primary tumors.</p></span></li><li><span>•</span><span><p>The results suggest the possibility that a germline mutation in an oncogene could facilitate the development of a tumor with additional mutations in the same oncogene.</p></span></li></ul></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424000500/pdfft?md5=3fc1e0067224b967458ed5d35f33c257&pid=1-s2.0-S1525730424000500-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer","authors":"Marcus Taylor ,&nbsp;Matt Evison ,&nbsp;Sarah Michael ,&nbsp;Emmanuel Obale ,&nbsp;Nils C. Fritsch ,&nbsp;Udo Abah ,&nbsp;Matthew Smith ,&nbsp;Glen P. Martin ,&nbsp;Michael Shackcloth ,&nbsp;Felice Granato ,&nbsp;Stuart W. Grant ,&nbsp;Northwest Thoracic Surgery Collaborative (NWTSC)","doi":"10.1016/j.cllc.2024.04.018","DOIUrl":"10.1016/j.cllc.2024.04.018","url":null,"abstract":"<div><h3>Background</h3><p>Measures of systemic inflammation (MSIs) have been developed and shown to help predict prognosis in patients with lung cancer. However, studies investigating the impact of MSIs on outcomes solely in cohorts of patients undergoing curative-intent resection of NSCLC are lacking. In the era of individualized therapies, targeting inflammatory pathways could represent a novel addition to the armamentarium of lung cancer treatment.</p></div><div><h3>Methods</h3><p>A multicentre retrospective review of patients who underwent primary lung cancer resection between 2012 and 2018 was undertaken. MSIs assessed were neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune inflammation index (SII), advanced lung cancer inflammation index (ALI), prognostic nutritional index (PNI) and haemoglobin albumin lymphocyte platelet (HALP) score. Cox regression analysis was performed to assess the impact of MSIs on overall survival.</p></div><div><h3>Results</h3><p>A total of 5029 patients were included in the study. Overall 90-day mortality was 3.7% (n = 185). All MSIs were significantly associated with overall survival on univariable analysis. After multivariable Cox regression analyses, lower ALI (expressed as a continuous variable) (HR 1.000, 95% CI 1.000-1.000, <em>P</em> = .049) and ALI &lt;366.43 (expressed as a dichotomous variable) (HR 1.362, 95% CI 1.137-1.631, <em>P</em> &lt; .001) remained independently associated with reduced overall survival.</p></div><div><h3>Conclusions</h3><p>MSIs have emerged in this study as potentially important factors associated with survival following lung resection for NSCLC with curative intent. In particular, ALI has emerged as independently associated with long-term outcomes. The role of MSIs in the clinical management of patients with primary lung cancer requires further investigation.</p></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141062688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}